Literature DB >> 12574378

Suppression of NF-kappa B activation and proinflammatory cytokine expression by Shiga toxin-producing Escherichia coli.

Nadja Hauf1, Trinad Chakraborty.   

Abstract

The NF-kappaB family of transcription factors forms one of the first lines of defense against infectious disease by inducing the expression of genes involved in inflammatory and immune responses. In this study, we analyzed the impact of Shiga toxin-producing Escherichia coli (STEC) on the NF-kappaB DNA-binding activity in HeLa cells. After a period of weak initial activation, DNA binding of NF-kappaB was actively suppressed by viable, E. coli secreted protein B (EspB)-secreting STEC. Sustained NF-kappaB activity was observed either using an isogenic mutant lacking EspB or after gentamicin-based killing of STEC after allowing bacterial attachment. These observations indicate that the ability of STEC to cause NF-kappaB activation is suppressed by a translocated bacterial effector protein, which is either EspB itself or requires EspB for delivery into the host cell. We found that STEC, enterohemorrhagic E. coli, and enteropathogenic E. coli all interfere with NF-kappaB activation initiated by TNF-alpha, indicating that suppression of signal-induced NF-kappaB activity is a property common to several attaching and effacing bacteria. As a consequence of NF-kappaB suppression, wild-type STEC induces significantly lower mRNA levels of IL-8, IL-6, and IL-1alpha upon prolonged infection periods compared with bacteria lacking EspB. For IL-8 and IL-6, the suppressive effect was also reflected at the level of cytokine secretion. Suppression of both basal and signal-induced NF-kappaB DNA binding by attaching and effacing-inducing bacteria appears to be an active strategy to counteract host defense responses, thus favoring intestinal colonization by these pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574378     DOI: 10.4049/jimmunol.170.4.2074

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Host immune status influences the development of attaching and effacing lesions in weaned pigs.

Authors:  Francis Girard; Isabelle P Oswald; Ionélia Taranu; Pierre Hélie; Greg D Appleyard; Josée Harel; John M Fairbrother
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Host inflammatory response inhibits Escherichia coli O157:H7 adhesion to gut epithelium through augmentation of mucin expression.

Authors:  Yansong Xue; Hanying Zhang; Hui Wang; Jia Hu; Min Du; Mei-Jun Zhu
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

3.  The Type III Effector NleD from Enteropathogenic Escherichia coli Differentiates between Host Substrates p38 and JNK.

Authors:  Kristina Creuzburg; Cristina Giogha; Tania Wong Fok Lung; Nichollas E Scott; Sabrina Mühlen; Elizabeth L Hartland; Jaclyn S Pearson
Journal:  Infect Immun       Date:  2017-01-26       Impact factor: 3.441

Review 4.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

5.  Enteropathogenic Escherichia coli-induced epidermal growth factor receptor activation contributes to physiological alterations in intestinal epithelial cells.

Authors:  Jennifer L Roxas; Athanasia Koutsouris; V K Viswanathan
Journal:  Infect Immun       Date:  2007-03-05       Impact factor: 3.441

6.  The type III secretion effector NleE inhibits NF-kappaB activation.

Authors:  Chen Nadler; Kobi Baruch; Simi Kobi; Erez Mills; Gili Haviv; Marganit Farago; Irit Alkalay; Sina Bartfeld; Thomas F Meyer; Yinon Ben-Neriah; Ilan Rosenshine
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

7.  The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65.

Authors:  Hayley J Newton; Jaclyn S Pearson; Luminita Badea; Michelle Kelly; Mark Lucas; Gavan Holloway; Kylie M Wagstaff; Michelle A Dunstone; Joan Sloan; James C Whisstock; James B Kaper; Roy M Robins-Browne; David A Jans; Gad Frankel; Alan D Phillips; Barbara S Coulson; Elizabeth L Hartland
Journal:  PLoS Pathog       Date:  2010-05-13       Impact factor: 6.823

Review 8.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

9.  Differences in adherence and virulence gene expression between two outbreak strains of enterohaemorrhagic Escherichia coli O157 : H7.

Authors:  Galeb S Abu-Ali; Lindsey M Ouellette; Scott T Henderson; Thomas S Whittam; Shannon D Manning
Journal:  Microbiology (Reading)       Date:  2009-11-05       Impact factor: 2.777

10.  Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function.

Authors:  Xiaofei Gao; Fengyi Wan; Kristina Mateo; Eduardo Callegari; Dan Wang; Wanyin Deng; Jose Puente; Feng Li; Michael S Chaussee; B Brett Finlay; Michael J Lenardo; Philip R Hardwidge
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.